SCHEMBL30167475

SCHEMBL30167475

CC(C)(C)OC(=O)N1CC(N2Cc3ccc(Br)cc3NC2=O)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 4/20 0.47
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
USP30 Q70CQ3 2/20 0.43
RORC P51449 2/20 0.42
MAPK1 P28482 1/20 0.41
NAMPT P43490 1/20 0.40
ESR2 Q92731 1/20 0.39
NR1H2 P55055 1/20 0.38
FPR3 P25089 1/20 0.38
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
GSK3B P49841 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
HDAC1 Q13547 1/20 0.38
CALCRL Q16602 3/20 0.37
KDM4E B2RXH2 1/20 0.37
SCN9A Q15858 1/20 0.37
RAMP1 O60894 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22716676 0.84 MAPK1 (0.55) DDB1CRBNRORCMAPK1NAMPT
SCHEMBL23092336 0.81 DPP4 (0.41) CALCRL
SCHEMBL5088976 0.81 FPR2 (0.50) FPR2DDB1CRBNMAPK1NAMPT
SCHEMBL31749583 0.80 FPR2 (0.48) FPR2DDB1CRBNUSP30RORC
SCHEMBL23092520 0.79 KRAS (0.40)
SCHEMBL20045530 0.77 USP30 (0.47) FPR2DDB1CRBNUSP30RORC
SCHEMBL28468990 0.76 DDB1 (0.47) FPR2DDB1CRBNRORCNAMPT
SCHEMBL20045979 0.75 FPR2 (0.42) FPR2DDB1CRBNUSP30RORC
SCHEMBL20045982 0.74 FPR2 (0.42) FPR2DDB1CRBNUSP30RORC
SCHEMBL2018122 0.74 FPR2 (0.43) FPR2CRBNUSP30RORCCCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630547-B2 RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications BIOTHERYX, INC. (US) 2026-05-19 US disclosed
US-20230002371-A1 RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630547-B2 RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications KRAS, RSU1, NRAS FPR2 3306/4885DDB1 1516/4885CRBN 245/4885
US-20230002371-A1 RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS KRAS, RSU1, RAB1A FPR2 3803/4885DDB1 1783/4885CRBN 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.